Veterinary Perceptions of Animal Health Monitoring Technologies in Clinical Practice: A US–UK–Germany Comparison
Objective
To understand veterinarians’ attitudes toward the adoption and clinical usefulness of animal monitoring technologies and compare:
- Perceived benefits
- Clinical applicability
- Economic and operational barriers
- Confidence in usage and interpretation
- Future intent to adopt or expand usage
The goal is to identify drivers and barriers that influence integration of continuous monitoring tools in veterinary care.
Methodology
Sample size: 150 veterinarians
- US: 50
- UK: 50
- Germany: 50
Practice type:
- Small animal practices: 68%
- Mixed: 22%
- Large animal / production: 10%
Instrument: 8-item Likert scale (1 = Strongly Disagree, 5 = Strongly Agree)
Data simulated: Based on known technology adoption trends, with the US more commercially driven and Germany more conservative and evidence-driven.
Question-by-Question Results (Likert Scale 1–5)
| Question | Overall Mean | US Mean | UK Mean | Germany Mean | Summary |
|---|---|---|---|---|---|
| 1. Animal monitoring improves early disease detection | 4.4 | 4.6 | 4.4 | 4.2 | High agreement |
| 2. Monitoring improves clinical outcomes and long-term care | 4.2 | 4.5 | 4.2 | 3.9 | US strongest |
| 3. Remote monitoring reduces in-clinic visits and cost burden | 3.8 | 4.2 | 3.7 | 3.4 | Moderate belief |
| 4. Data from monitoring systems is accurate and reliable | 3.5 | 3.8 | 3.5 | 3.2 | Reliability concerns |
| 5. Monitoring systems integrate well with practice workflows and systems | 3.2 | 3.6 | 3.3 | 2.8 | Workflow integration weak |
| 6. Cost is a barrier to adoption | 4.3 | 3.9 | 4.4 | 4.7 | Strong barrier, highest in Germany |
| 7. I am confident interpreting and acting on monitoring data | 3.6 | 4.0 | 3.6 | 3.2 | Training gap noted |
| 8. I expect to increase use of monitoring technologies in next 12 months | 4.0 | 4.4 | 4.1 | 3.5 | Growth strongest in US/UK |
United States 🇺🇸
Commercial optimism and proactive integration.
- Highest adoption confidence and future investment intent.
- Seen as a competitive differentiator and value-added service.
- Cost is a barrier but offset by strong client demand and insurance use.
Theme: Commercial optimism and proactive integration.
United Kingdom 🇬🇧
Cautious but growing adoption.
- Moderately positive and evidence-driven approach.
- Adoption tied to clinical justification, animal welfare protocols, and regulated use cases.
- Cost and workflow integration remain concerns, but momentum increasing.
Theme: Cautious but growing adoption with clinical justification required.
Germany 🇩🇪
Evidence-focused, slower adoption.
- Strong agreement on clinical benefits—but lowest confidence and readiness to adopt.
- Cost, regulation, and skepticism about data accuracy slow implementation.
- Strong preference for validated evidence and standardized protocols.
Theme: Clinically positive but constrained by cost, regulation, and evidence requirements.
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
